ASX Health Stocks: Biotron jumps 15pc after hitting primary objectives of Phase 2 trial

ASX Health Stocks: Immutep sinks 35pc despite positive results from cancer-treatment trial

stockhead.com.au - 27/Jun 01:53

Immutep sinks 35pc despite revealing positive topline results for cancer-treatment trial. Investors may have had higher expectations. ...

Cartesian Therapeutics doses first patient in phase 2 clinical trial of Descartes─08 to treat systematic lupus erythematosus

pharmabiz.com - 00:00

Cartesian Therapeutics, Inc, a clinical─stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, announced that the first...

ASX Health Stocks: Proteomics to start selling in France; Recce to start clinical trials

stockhead.com.au - 24/Jun 01:59

Proteomics to start selling in France, Recce granted ethical approval for clinical trials, and EMV gets $1.25m grant. ...

Go Hub jumps as high as 148pct on ACE market debut

nst.com.my - 03/Jul 10:14

KUALA LUMPUR: Go Hub Capital Bhd, which debuted on the ACE Market this morning, jumped as much as 148 per cent to 87 sen a share from its initial...

Syneos Health - USA: Principal Clinical Trial Manager - Early Phase

pharmiweb.com - 28/Jun 00:00

Competitive: Syneos Health - USA: Principal Clinical Trial Manager - Ophthalmology Syneos Health® is a leading fully integrated biopharmaceutical...

ASX wellness stocks offering calm and anxiety relief – Part 2

stockhead.com.au - 23/Jun 20:45

While many Aussies turn to health professionals for mental health and stress, the ASX wellness sector is also looking to ...

Wall Street drifts after French market jumps on election results

washingtontimes.com - 01/Jul 15:47

U.S. stocks are drifting Monday after the French market rallied, as elections continue to drive swings in financial markets worldwide.

First Patient Dosed in the MAD Part 2 Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

drugs.com - 26/Jun 19:06

CAMBRIDGE, Mass., June 26, 2024. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic...

Promising results from the Phase 2 study of novel extended-release ketamine tablets (R-107) for Treatment-Resistant Depression accepted for publication by Nature Medicine

drugs.com - 24/Jun 23:06

AUCKLAND, New Zealand, June 24, 2024. Douglas Pharmaceuticals, New Zealand's largest pharmaceutical company, is pleased to announce that results from...

Mexican madness adds spice to top ASX performers

smh.com.au - 21/Jun 06:37

This week’s Bulls N’ Bears ASX Runner of the Week is … Schrole Group. Its shares jumped 187.5 per cent, while the new listing of Guzman y Gomez...

Rubriques :